...
首页> 外文期刊>Physiological Reports >Linaclotide activates guanylate cyclase?¢????C/cGMP/protein kinase?¢????II?¢????dependent trafficking of CFTR in the intestine
【24h】

Linaclotide activates guanylate cyclase?¢????C/cGMP/protein kinase?¢????II?¢????dependent trafficking of CFTR in the intestine

机译:利那洛肽激活鸟苷酸环化酶-C / cGMP /蛋白激酶-II-依赖肠内CFTR的运输

获取原文

摘要

The transmembrane receptor guanylyl cyclase?¢????C (GC?¢????C), expressed on enterocytes along the intestine, is the molecular target of the GC?¢????C agonist peptide linaclotide, an FDA?¢????approved drug for treatment of adult patients with Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation. Polarized human colonic intestinal cells (T84, CaCo?¢????2BBe) rat and human intestinal tissues were employed to examine cellular signaling and cystic fibrosis transmembrane conductance regulator (CFTR)?¢????trafficking pathways activated by linaclotide using confocal microscopy, in????vivo surface biotinylation, and protein kinase?¢????II (PKG?¢????II) activity assays. Expression and activity of GC?¢????C/cGMP pathway components were determined by PCR, western blot, and cGMP assays. Fluid secretion as a marker of CFTR cell surface translocation was determined using in????vivo rat intestinal loops. Linaclotide treatment (30????min) induced robust fluid secretion and translocation of CFTR from subapical compartments to the cell surface in rat intestinal loops. Similarly, linaclotide treatment (30????min) of T84 and CaCo?¢????2BBe cells increased cell surface CFTR levels. Linaclotide?¢????induced activation of the GC?¢????C/cGMP/PKGII signaling pathway resulted in elevated intracellular cGMP and pVASP ser239 phosphorylation. Inhibition or silencing of PKGII significantly attenuated linaclotide?¢????induced CFTR trafficking to the apical membrane. Inhibition of protein kinase?¢????A (PKA) also attenuated linaclotide?¢????induced CFTR cell surface trafficking, implying cGMP?¢????dependent cross?¢????activation of PKA pathway. Together, these findings support linaclotide?¢????induced activation of the GC?¢????C/cGMP/PKG?¢????II/CFTR pathway as the major pathway of linaclotide?¢????mediated intestinal fluid secretion, and that linaclotide?¢????dependent CFTR activation and recruitment/trafficking of CFTR from subapical vesicles to the cell surface is an important step in this process.
机译:跨肠受体鸟苷酰环化酶C(GC→C→C)在肠道小肠细胞上表达,是GC→C→激动剂肽利那洛肽的分子靶标。批准的药物用于治疗患有便秘和慢性特发性便秘的成人肠易激综合征的患者。使用极化的人结肠肠道细胞(T84,CaCo 3-2BBe)大鼠和人肠道组织检查共聚焦的利那洛肽激活的细胞信号传导和囊性纤维化跨膜电导调节剂(CFTR)的贩运途径。显微镜,体内表面生物素化和蛋白激酶II(PKG -II)活性测定。 GC,C / cGMP途径成分的表达和活性通过PCR,蛋白质印迹和cGMP测定法确定。使用体内大鼠肠loop确定作为CFTR细胞表面易位标记的液体分泌。利那洛肽处理(30分钟)可诱导大鼠肠loop中健壮的液体分泌和CFTR从根尖下隔室到细胞表面的转运。同样,T84和CaCo 3 + 2BBe细胞的利那洛肽处理(30分钟)能增加细胞表面的CFTR水平。利那洛肽诱导的GC / C / cGMP / PKGII信号通路的激活导致细胞内cGMP和pVASP ser239磷酸化升高。 PKGII的抑制或沉默显着减弱了利那洛肽诱导的CFTR向顶端膜的运输。抑制蛋白激酶A(PKA)也减弱了利那洛肽诱导的CFTR细胞表面运输,这暗示了cGMP依赖PKA途径的交叉交叉激活。这些发现共同支持利那洛肽的诱导的GC活化,C / cGMP / PKG的II / CFTR途径是利那洛肽的主要途径。介导的肠液分泌,以及那那洛肽依赖的CFTR活化和CFTR从根尖下囊泡到细胞表面的募集/贩运是该过程中的重要步骤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号